New approaches to development of mucosal vaccine against enteric bacterial pathogens; preventing campylobacteriosis

• Autorzy: Jagusztyn-Krynicka E K , Wyszynska A. , Raczko A.
• Języki publikacji: EN

Abstrakty

EN

Although vaccination, after having been more than 200 years in medical practice, has proven to be the most effective and the cheapest way to prevent infectious diseases, they remain still the main cause of human premature deaths. As many pathogens enter the human body through the mucosal surfaces, the mucosal way of immunization is considered to be the most promising strategy to decrease the number of human infections. Moreover, the oral delivery system eliminates the necessity of injection what is extremely important for pediatric immunization programs. However, most of recently constructed subunit vaccines based on purified bacterial/viral antigens are rather poorly immunogenic. This review presents some novel ways to enhance and modulate host immune responses by combining antigens with specific adjuvants or by employing specific delivery systems. We also discuss some recent technologies, based on mining the genomic sequences of bacterial pathogens, which accelarate and improve identification of new candidates for vaccine construction. As an example, we focus on the progress in the development of vaccine against Campylobacter spp. Campylobacter jejuni is now recognized as a leading cause of bacterial enteritis in human.

Słowa kluczowe

EN

antigen carrier; human disease; Campylobacter jejuni; bacterial pathogen; vaccine; antibiotic; Campylobacter; campylobacteriosis; infectious disease; specific adjuvant; mucosal vaccine

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2004
• Tom: 53
• Numer: Suppl.
• Opis fizyczny: p.7-15,ref.

Twórcy

autor

Jagusztyn-Krynicka E K

• Warsaw University, Miecznikowa 1 str., 02-096 Warsaw, Poland

autor

Wyszynska A.

autor

Raczko A.

Bibliografia

• Aarestrup F.M. and H.C. Wegener. 1999. The effects of antibiotic usage in food animals on the development of antimicrobial resistance of importance for humans in Campylobacter and Escherichia coli. Microbes Infect. I: 639-644.
• Altekruse S.F., N.J. Stern, P.I. Fields and D.L. Swerdlow. 1999. Campylobacterjejuni-an emerging foodborne pathogen. Emerg. Infect. Dis. 5: 28-35.
• Autenrieth I.B. and M.A. Schmidt. 2000. Bacterial interplay at intestinal mucosal surfaces: implications for vaccine development. Trends Microbiol. 8: 457-464.
• Baqar S., L.A. Apple bee and A.L. Bourgeois. 1995a. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect. Immun. 63: 3731-3735.
• Baqar S., A.L. Bourgeois, P.J. Schultheiss, R.I. Walker, D.M. Rollins, R.L. Haberberger and O.R. Pavlovskis. 1995b. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 13: 22-28.
• Bumann D., C. Hueck, T. Aebischer and T.F. Meyer. 2000. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol. Med. Microbiol. 27: 357-364.
• Chiang S.L., J.J. Mekalanos and D.W. Hoi den. 1999. In vivo genetic analysis of bacterial virulence. Annu. Rev. Microbiol. 53: 129-154.
• Coker A.O., R.D. Isokpehi, B.N. Thomas, K.O. Amisu and C.L. Obi. 2002. Human campylobacteriosis in developing countries. Emerg. Infect. Dis. 8: 237-244.
• Corry J.E. and H.I. Atabay. 2001. Poultry as a source of Campylobacter and related organisms. Symp. Ser. Soc. Appl. Microbiol. 96S-114S.
• Curtiss R., 3rd and J.O. Hassan. 1996. Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Vet. Immunol. Immunopathol. 54: 365-372.
• Dietrich G., M. Griot-Wenk, I.C. Metcalfe, A.B. Lang and J.F. Viret. 2003. Experience with registered mucosal vaccines. Vaccine 21: 678-683.
• Dittmer U. and A.R. Olbrich. 2003. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. Microbiol. 6: 472-477.
• Dorrell N., J.A. Mangan, K.G. Laing, J. Hinds, D. Linton, H. Al-Ghusein, B.G. Barrell, J. Parkhill, N.G. Stoker, A.V. Karlyshev, P.D. Butcher and B.W. Wren. 2001. Whole genome comparison of Campylobacter jejuni human isolates using a low-cost microarray reveals extensive genetic diversity. Genome Res. 11: 1706-1715.
• Douce G., M.M. Giuliani, V. Giannelli, M.G. Pizza, R. Rappuoli and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16: 1065-1073.
• Duim B., C.W. Ang, A. van Belkum, A. Rigter, N.W. van Leeuwen, H.P. Endtz and J.A. Wagenaar. 2000. Amplified fragment length polymorphism analysis of Campylobacter jejuni strains isolated from chickens and from patients with gastroenteritis or Guillain-Barre or Miller Fisher syndrome. Appl. Environ. Microbiol. 66: 3917-3923.
• Engberg J., F.M. Aarestrup, D.E. Taylor, P. Gerner-Smidt and I. Nachamkin. 2001. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg. Infect. Dis. 7: 24-34.
• Freytag L.C. and J.D. Clements. 1999. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236: 215-236.
• Garmory H.S., K.A. Brown and R.W. Tit ball. 2002. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. 26: 339-353.
• Gaynor E.C., S. Cawthraw, G. Manning, J.K. MacKichan, S. Falkow and D.G. Newell. 2004. The genome-sequenced variant of Campylobacter jejuni NCTC 11168 and the original clonal clinical isolate differ markedly in colonization, gene expression, and virulence-associated phenotypes. J. Bacteriol. 186: 503-517.
• Gentschev I., G. Dietrich and W. Goebel. 2002. The E. coli alpha-hemolysin secretion system and its use in vaccine development. Trends Microbiol. 10: 39-45.
• Green B.A. and S.M. Baker. 2002. Recent advances and novel strategies in vaccine development. Curr. Opin. Microbiol. 5: 483-488.
• Jakobsen H., D. Schulz, M. Pizza, R. Rappuoli and I. Jonsdollir. 1999. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Inject. Immun. 67: 5892-5897.
• Jiang W., H.J. Baker and B.F. Smith. 2003. Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. 71: 40-46.
• Karlyshev A.V., P. Everest, D. Linton, S. Cawthraw, D.G. Newell and B.W. Wren. 2004. The Campylobacter jejuni general glycosylation system is important for attachment to human epithelial cells and in the colonization of chicks. Microbiology 150: 1957-1964.
• Khoury C.A. and R.J. Meinersmann. 1995. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian Dis. 39: 812-820.
• Klinman D.M., D. Currie, I. Gursel and D. Verthelyi. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199: 201-216.
• Kochi S.K., K.P. Killeen and U.S. Ryan. 2003. Advances in the development of bacterial vector technology. Expert. Rev. Vaccines. 2: 31-43.
• Lee L.H., E. Burg, 3rd, S. Baqar, A.L. Bourgeois, D.H. Burr, CP. Ewing, T.J. Trust and P. Guerry. 1999. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect. Immun. 67: 5799-5805.
• Marinaro M., H.F. Staats, T. Hiroi, R.J. Jackson, M. Coste, P.N. Boyaka, N. Okahashi, M. Y am am o to, H. Kiyono and H. Bluethmann. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155: 4621-4629.
• McCluskie M.J. and H.L. Davis. 1999. Mucosal immunization with DNA vaccines. Microbes Infect. 1: 685-698.
• Millar D.G., T.R. Hirst and D.P. Snider. 2001. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin. Infect. Immun. 69: 3476-3482.
• Mora M., D. Veggi, L. Santini, M. Pizza and R. Rappuoli. 2003. Reverse vaccinology. Drug Discov. Today 8: 459-464.
• Nachamkin I., B.M. Alios and T. Ho. 1998. Campylobacter species and Guillain-Barre syndrome. Clin. Microbiol. Rev. 11: 555-567.
• Newell D.G. and J.A. Wagenaar. 2000. Poultry infections and their control at the farm level, p. 497-509. In: I. Nachamkin and M.J. Blaser, Poultry infections and their control at the farm level. Washington, DC, American Society for Microbiology.
• Pallen M.J., A.C. Lam, N.J. Lorn an and A. McBride. 2001. An abundance of bacterial ADP-ribosyltransferases - implications for the origin of exotoxins and their human homologues. Trends Microbiol. 9: 302-307.
• Parkhill J., B.W. Wren, K. Mungall, J.M. Ketley, C. Churcher, D. Basham, T. Chillingworth, R.M. Davies, T. Feltwell, S. Holroyd, K. Jagels, A.V. Karlyshev, S. Moule, M.J. Pallen, C.W. Penn, M.A. Quail, M.A. Rajandream, K.M. Rutherford, A.H. van Vliet, S. Whitehead and B.G. Barrell. 2000. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 403: 665-668.
• Pawelec D., J. Jakubowska-Mroz and E.K. Jagusztyn-Krynicka. 1998. Campylobacter jejuni 72Dz/92 cjaC gene coding 28 kDa immunopositive protein, a homologue of the solute-binding components of the ABC transport system. Lett. Appl. Microbiol. 26: 69-76.
• Pawelec D., E. Rozynek, J. Popowski and E.K. Jagusztyn-Krynicka. 1997. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS Immunol. Med. Microbiol. 19: 137-150.
• Periwal S.B., K.R. Kourie, N. Ramachandaran, S.J. Blakeney, S. De Bruin, D. Zhu, T.J. Zamb, L. Smith, S. Udem, J.H. Eldridge, K.E. Shroff and P.A. Reilly. 2003. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine 21: 376-385.
• Peterson J.W., R.A. Finkelstein, J. Cantu, D.L. Gessell and A.K. Chopra. 1999. Cholera toxin B subunit activates arachidonic acid metabolism. Inject. Immun. 67: 794-799.
• Petrovska L., L. Lopes, CP. Simmons, M. Pizza, G. Dougan and B.M. Chain. 2003. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21: 1445-1454.
• Pizza M., M.M. Giuliani, M.R. Font ana, E. Monaci, G. Douce, G. Dougan, K.H. Mills, R. Rappuoli and G. Del Giudice. 2001. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
• Pouwels PH., R.J. Leer, M. Shaw, M.J. Heijne den Bak-Glashouwer, F.D. Tielen, E. Smit, B. Martinez, J. Jore and PL. Conway. 1998. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int. J. Food Microbiol. 41: 155-167.
• Raczko A.M., J.M. Bujnicki, M. Pawlowski, R. Godlewska, M. Lewandowska and E.K. Jagusztyn-Krynicka. 2004. Characterisation of new DsbB-like thiol-oxidoreductases of Campylobacter jejuni and Helicobacter pylori and classification of the DsbB family based on phylogenomic, structural and functional criteria. Microbiology (accepted)
• Rice B.E., D.M. Rollins, E.T. Mallinson, L. Carr and S.W. Joseph. 1997. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine 15: 1922-1932.
• Sahin O., N. Luo, S. Huang and Q. Zhang. 2003. Effect of Campylobacter-specific maternal antibodies on Campylobacter jejuni colonization in young chickens. Appl. Environ. Microbiol. 69: 5372-5379.
• Scott D.A., S. Baqar, G. Pazzaglia, P. Guerry and D.H. Burr. 1997. Vaccines against Campylobacter jejuni, p. 885-896. In: M.M. Levine, G.C. Woodrow, J.B. Kaper and G.S. Cobon, New generation vaccines - 2nd edition, revised and expanded. New York, Basel, Hong-Kong, Marcel Dekker Inc.
• Skirrow M.B. and M.J. Blaser. 2000. Clinical aspects of Campylobacter infection, p. 69-89. In: I. Nachamkin, M.J. Blaser and L.S. Tompkins, Clinical aspects of Campylobacter infection. Washington, ASM Press.
• Steidler L. 2003. Genetically engineered probiotics. Best Pract. Res. Clin. Gastroenterol. 17: 861-876.
• Szymanski CM., S.M. Logan, D. Linton and B.W. Wren. 2003. Campylobacter-a tale of two protein glycosylation systems. Trends Microbiol. 11: 233-238.
• Taylor L.H., S.M. Latham and M.E. Woolhouse. 2001. Risk factors for human disease emergence. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356: 983-989.
• Underhill D.M. and A. Ozinsky. 2002. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol. 14: 103-110.
• Wacker M., D. Linton, P.G. Hitchen, M. Nita-Lazar, S.M. Haslam, S.J. North, M. Panico, H.R. Morris, A. Dell, B.W. Wren and M. Aebi. 2002. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298: 1790-1793.
• Wagner H. 2002. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5: 62-69.
• Weltzin R., B. Gay, W.D. Thomas, P.J. Giannasca and P.M. Thomas. 2000. Parenteral adjuvant activates of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 68: 2775-2782.
• Wizemann T.M., J.H. Heinrichs, J.E. Adamou, A.L. Erwin, C. Kunsch, G.H. Choi, S.C. Barash, C.A. Rosen, H.R. Masure, E. Tuomanen, A. Gayle, YA. Brewah, W. Walsh, P. Barren, R. Lathigra, M. Hanson, S. Langermann, S. Johnson and S. Koenig. 2001. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69: 1593-1598.
• Woolhouse M.E. 2002. Population biology of emerging and re-emerging pathogens. Trends Microbiol. 10: S3-7.
• Wren B.W., D. Linton, N. Dorrell and A.V. Karlyshev. 2001. Post genome analysis of Campylobacter jejuni. Symp. Ser. Soc. Appl. Microbiol. 36S-44S.
• Wu H.Y and M.W. Russell. 1998. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16: 286-292.
• Wyszynska A., D.P. Pawelec and E.K. Jagusztyn-Krynicka. 2002. Immunological characterization of the Campylobacter jejuni 72Dz/92 cjaD gene product and its fusion with B subunit of E. coli LT toxin. Acta Microbiol. Pol. 51: 313-326.
• Wyszynska A., A. Raczko, M. Lis and E.K. Jagusztyn-Krynicka. 2004. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine 22: 1379-1389.
• Ziprin R.L., C.R. Young, J.A. Byrd, L.H. Stanker, M.E. Hume, S.A. Gray, B.J. Kim and M.E. Konkel. 2001. Role of Campylobacter jejuni potential virulence genes in cecal colonization. Avian Dis. 45: 549-557.
• Ziprin R.L., C.R. Young, L.H. Stanker, M.E. Hume and M.E. Konkel. 1999. The absence of cecal olonization of chicks by a mutant of Campylobacter jejuni not expressing bacterial fibronectin-binding protein. Avian Dis. 43: 586-589.
• Ziprin R.L., R.B. Harvey, M.E. Hume and L.E. Kubena. 2002. Campylobacter colonization of the crops of newly hatched leghorn chicks. Avian Dis. 46: 985-988.